Review examines Amazonian phytotherapy for cancer fatigue
Bottom line
A new narrative review in Integrative Cancer Therapies examines whether Amazonian and related plant-based therapies could help manage cancer-related fatigue, a common and hard-to-treat symptom in oncology. The review, led by Auro Del Giglio, pulls together clinical and mechanistic evidence on botanical approaches such as guaraná and other herbal products, arguing that interest is growing because standard drug options for cancer-related fatigue remain limited. But the broader evidence base is still mixed: a recent systematic review and meta-analysis of 14 randomized trials found only a modest overall benefit for phytotherapy, with substantial heterogeneity, high or unclear risk of bias in many studies, and no statistically significant benefit for guaraná or ginseng in subgroup analyses. Current ASCO–Society for Integrative Oncology guidance says clinicians may recommend American ginseng for adults undergoing active cancer treatment, while evidence remains insufficient for or against guaraná. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is a useful signal about where integrative oncology research is heading, but not a practice-changing development on its own. Companion animal cancer care increasingly overlaps with pet parent interest in supplements and “natural” fatigue support, so reviews like this can help clinicians frame evidence-based conversations. The main takeaway is caution: biologic plausibility and early trial signals exist, especially around guaraná’s stimulant and anti-inflammatory properties, yet major oncology guidance still prioritizes exercise, psychosocial support, and other nonpharmacologic strategies over most herbal products because efficacy and safety data remain limited. (ascopubs.org)
What to watch: Watch for better-designed, multicenter trials, and for whether future guidelines move any specific botanical, including guaraná, from “insufficient evidence” toward a clearer recommendation. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Article type
- Narrative review
- Journal
- Integrative Cancer Therapies
- Topic
- Amazonian and related phytotherapy for cancer-related fatigue
- Lead author
- Auro Del Giglio
- Key botanical
- Guaraná (Paullinia cupana)
- Evidence summary
- A 2025 systematic review and meta-analysis of 14 randomized controlled trials found only a modest overall benefit for phytotherapy
- Guaraná finding
- No statistically significant subgroup benefit for guaraná
- Guideline position
- ASCO–Society for Integrative Oncology says evidence is insufficient for or against guaraná
- Alternative guideline note
- Clinicians may recommend American ginseng for adults undergoing active cancer treatment
A new narrative review in Integrative Cancer Therapies puts a spotlight on Amazonian and related phytotherapy for cancer-related fatigue, a symptom that can persist during and after treatment and remains difficult to manage with conventional drugs alone. The paper, by Auro Del Giglio, reflects continued interest in whether plant-derived therapies, particularly botanicals with stimulant, anti-inflammatory, or adaptogenic properties, might fill a gap in supportive oncology care. (pubmed.ncbi.nlm.nih.gov)
That interest has been building for years. Cancer-related fatigue is widely recognized as one of the most burdensome symptoms in oncology, and existing guidelines have generally emphasized nonpharmacologic approaches first, including exercise, psychological support, and symptom management. Herbal and supplement-based options have attracted attention because fatigue is multifactorial, involving inflammatory, metabolic, neuroendocrine, and psychological drivers, but the evidence has been inconsistent across products, cancer types, and study designs. (ascopubs.org)
The Amazonian angle is especially tied to guaraná (Paullinia cupana), a plant native to the Amazon basin that has been studied in cancer populations by Del Giglio and colleagues. Earlier randomized studies in breast cancer suggested possible improvements in fatigue scores with guaraná during chemotherapy, helping establish the rationale for continued study. But later evidence has been less definitive. A systematic review focused on guaraná concluded that available trials were small and methodologically limited, and a broader 2025 systematic review and meta-analysis of 14 randomized controlled trials found that phytotherapy overall produced only a modest improvement in fatigue, with very low certainty of evidence and no statistically significant subgroup benefit for guaraná or ginseng. (journals.sagepub.com)
That puts the new review in an important context: it is less a declaration that these products work than a synthesis of why researchers remain interested despite weak or uneven trial data. Mechanistically, botanicals may affect inflammation, oxidative stress, mitochondrial function, neurotransmission, or hypothalamic-pituitary-adrenal signaling, all pathways implicated in cancer-related fatigue. Clinically, though, the field is still dealing with small trials, mixed endpoints, variable formulations, and inconsistent controls, which makes it hard to translate promising biology into confident bedside recommendations. (pubmed.ncbi.nlm.nih.gov)
Outside reaction from the oncology community has been measured rather than enthusiastic. The Oncology Nursing Society, summarizing recent evidence in July 2026, said herbal medicine for cancer-related fatigue remains heterogeneous and limited by sparse long-term safety data in oncology populations. Meanwhile, the ASCO–Society for Integrative Oncology guideline update allows clinicians to recommend American ginseng at 2,000 mg daily for adults undergoing active cancer treatment, but says evidence is insufficient to recommend for or against guaraná. Other guideline summaries similarly note that guaraná is not currently recommended as standard fatigue management. (ons.org)
Why it matters: For veterinary professionals, this review is most relevant as a window into client expectations and the direction of integrative supportive-care research, not as a direct model for veterinary use. Pet parents facing cancer treatment for a dog or cat may ask about herbal products for energy, appetite, or quality of life, especially as human oncology coverage around botanicals expands. This review reinforces the need for careful counseling: “natural” does not mean well-proven, formulations are not standardized, and herb-drug interactions can matter in oncology. For clinicians in veterinary oncology, rehabilitation, and palliative care, the practical lesson is to stay grounded in symptom assessment, nutrition, pain control, activity support, and transparent discussion of uncertainty when supplements come up. (ascopubs.org)
There’s also a translational research angle. If human oncology continues to explore phytotherapy for fatigue, veterinary researchers may eventually ask similar questions in companion animals with cancer, particularly around quality-of-life endpoints. But the human literature suggests that any such work would need rigorous trial design from the start, including standardized extracts, adverse-event reporting, and clear differentiation between fatigue caused by disease, chemotherapy, anemia, pain, sleep disruption, or cachexia. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next meaningful milestone will be whether larger randomized trials can identify a specific botanical, patient subgroup, or treatment setting where benefit is reproducible, and whether future oncology guidelines revise their current cautious stance on guaraná and related products. (pubmed.ncbi.nlm.nih.gov)